The phase 4 PADMA study showed meaningful improvements in TFF and PFS in patients with high-risk HR-positive/HER2-negative metastatic breast cancer.
The FDA approved inavolisib for triplet combination use for treatment of PIK3CA-mutated locally advanced or metastatic ...
The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback